Trade Names:Trizivir- Tablets abacavir sulfate 300 mg/lamivudine 150 mg/zidovudine 300 mg
Inhibits replication of HIV by incorporation into HIV DNA and production of incomplete, nonfunctional DNA.
Rapidly absorbed and extensively distributed. Oral bioavailability 86%.Lamivudine
Rapidly absorbed and extensively distributed. Oral bioavailability 86%.Zidovudine
Rapidly absorbed and extensively distributed. Oral bioavailability 64%.
Binding of abacavir to human plasma proteins is approximately 50%. Binding of abacavir to plasma proteins was independent of concentration. Vd approximately 0.86 L/kg.Lamivudine
Binding to plasma protein is low. Vd approximately 1.3 L/kg.Zidovudine
Binding to plasma protein is low. Vd approximately 1.6 L/kg.
In humans, abacavir, lamivudine, and zidovudine are not significantly metabolized by CYP-450 enzymes.Abacavir
The primary routes of elimination of abacavir are metabolism by alcohol dehydrogenase to form the 5'-carboxylic acid and glucuronyl transferase to form the 5'-glucuronide.Lamivudine
Approximately 70% of an intravenous dose of lamivudine is recovered as unchanged drug in the urine. Metabolism of lamivudine is a minor route of elimination. In humans, the only known metabolite is the trans-sulfoxide metabolite (approximately 5% of an oral dose after 12 hours).Zidovudine
Zidovudine is eliminated primarily by hepatic metabolism. The major metabolite of zidovudine is 3'-azido-3'-deoxy-5'-O-β-D-glucopyranuronosylthymidine (GZDV). GZDV AUC is about 3-fold greater than the zidovudine AUC.
Abacavir approximately 0.8 L/h/kg; lamivudine approximately 0.33 L/h/kg; zidovudine approximately 1.6 L/h/kg.Renal Cl
Abacavir approximately 0.007 L/h/kg; lamivudine approximately 0.22 L/h/kg; zidovudine approximately 0.34 L/h/kg.Elimination half-life
Abacavir approximately 1.45 h; lamivudine 5 to 7 h; zidovudine 0.5 to 3 h.Food effects
Administration of abacavir/lamivudine/zidovudine with food did not alter the extent of abacavir, lamivudine, and zidovudine absorption (AUC), as compared with administration under fasted conditions.
Use alone or in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Patients with hepatic impairment; patients with previously demonstrated hypersensitivity to abacavir or any component of the product; never restart any abacavir-containing product following a hypersensitivity reaction, regardless of HLA-B*570 status.
PO 1 tablet twice daily.
Store at controlled room temperature (59° to 86°F).
Zidovudine plasma concentrations may be reduced, decreasing the pharmacologic effects.Atovaquone, fluconazole, methadone, probenecid, valproic acid
Zidovudine plasma concentrations may be elevated, increasing the pharmacologic and adverse reactions.Doxorubicin, ribavirin, stavudine
Antagonistic relationship has been demonstrated between these agents and zidovudine.Ethanol
Abacavir plasma concentrations may be elevated, increasing the pharmacologic and adverse reactions.Food
When administered with a high-fat meal, the abacavir, lamivudine, and zidovudine C max may be decreased; however, Trizivir may be given with or without food.Ganciclovir, interferon-alpha, other bone marrow suppressive or cytotoxic agents
May increase the hematologic toxicity of zidovudine.Methadone
Abacavir may increase methadone Cl, necessitating a dosage increase in some patients.Phenytoin
Zidovudine Cl may be decreased. Phenytoin levels may increase, decrease, or not change.Trimethoprim/sulfamethoxazole
Serum concentrations of lamivudine may be elevated, increasing the pharmacologic and adverse reactions.Zalcitabine
Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of each other.
None well documented.
Headache (13%); fatigue, malaise (12%); depression (6%); anxiety (5%); dizziness, insomnia and other sleep disorders, paresthesia, peripheral neuropathy, seizures (postmarketing).
Skin rash (5%); alopecia, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria (postmarketing).
Ear/nose/throat infections (5%).
Nausea (19%); nausea/vomiting (10%); diarrhea (7%); abdominal pain, anorexia, decreased appetite, dyspepsia, oral mucosal pigmentation, stomatitis (postmarketing).
Anemia, aplastic anemia, lymphadenopathy, splenomegaly, thrombocytopenia (postmarketing).
Elevated bilirubin, elevated transaminases, hepatic steatosis, lactic acidosis, pancreatitis, posttreatment exacerbation of hepatitis (postmarketing).
Elevated CPK (7%); increased ALT (6%); neutropenia (5%); hyperamylasemia, hypertriglyceridemia (2%).
Body accumulation/fat redistribution, hyperglycemia (postmarketing).
Musculoskeletal pain (5%); arthralgia, muscle weakness, myalgia, rhabdomyolysis (postmarketing).
Viral respiratory infections (5%); abnormal breath sounds/wheezing (postmarketing).
Hypersensitivity (8%); fever/chills (6%); anaphylaxis, vasculitis, weakness (postmarketing).
Intended only for patients whose regimen would otherwise include abacavir, lamivudine, and zidovudine.Hypersensitivity reactions
Serious and sometimes fatal hypersensitivity reactions have been associated with abacavir. The reaction is a multi-organ clinical syndrome usually characterized by a sign or symptom in 2 or more of the following groups: (1) fever; (2) rash; (3) GI, including abdominal pain, diarrhea, nausea, or vomiting; (4) constitutional, including achiness, fatigue, or generalized malaise; (5) respiratory, including cough, dyspnea, or pharyngitis. Discontinue Trizivir as soon as a hypersensitivity reaction is suspected. Permanently discontinue Trizivir if hypersensitivity cannot be ruled out, even when other diagnoses are possible. Patients carrying the HLA-B*5710 allele are at a high risk for experiencing a hypersensitivity reaction to abacavir.
Following a hypersensitivity reaction to abacavir, never restart Trizivir or any other abacavir-containing product because more severe symptoms can occur within hours and may include life-threatening hypotension and death.
Reintroduction of Trizivir or any other abacavir-containing product, even in patients who have no identified history or unrecognized symptoms of hypersensitivity to abacavir therapy, can result in serious or fatal hypersensitivity reactions.Hematologic toxicity
Zidovudine has been associated with hematologic toxicity, including neutropenia and severe anemia. Prolonged zidovudine use has been associated with symptomatic myopathy.Lactic acidosis and severe hepatomegaly
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with use of nucleoside analogues alone or in combination.Exacerbations of hepatitis B
Severe acute exacerbations of hepatitis B have been reported in patients coinfected with hepatitis B virus (HBV) and HIV who have discontinued lamivudine. Closely monitor hepatic function with clinical and laboratory follow-up for at least several months in patients who discontinue Trizivir and are coinfected with HIV and HBV. Initiation of anti–hepatitis B therapy may be warranted.
Frequently monitor blood cell counts in patients with advanced HIV disease and in patients receiving combination therapy with Trizivir , interferon alpha, and ribavirin. Periodically monitor blood cell counts in HIV-infected patients with asymptomatic or early HIV disease.Hepatic
Monitor patients with coinfection with HBV and HIV for posttreatment exacerbations of hepatitis B for several months after stopping treatment. Closely monitor patients receiving combination therapy with Trizivir , interferon alpha, and ribavirin; hepatic decompensation has been reported.Hypersensitivity reaction
Monitor patient for signs/symptoms of allergic reaction to abacavir. Discontinue use if a sign or symptom in 2 or more of the following groups is noted: fever; rash; GI, including abdominal pain, diarrhea, nausea, or vomiting; constitutional, including achiness, fatigue, or generalized malaise; and respiratory, including cough, dyspnea, or pharyngitis. If hypersensitivity reaction is documented, ensure the reaction is reported to Abacavir Hypersensitivity Registry as noted in the package insert.Lactic acidosis
Monitor patient for signs/symptoms of lactic acidosis (profound weakness or tiredness; unexpected stomach discomfort; feeling cold, dizzy, or light-headed; slow or irregular heartbeat). Withhold drug if suspected.
Category C .
HIV-infected mothers should not breast-feed their infants.Abacavir
Undetermined.Lamivudine and zidovudine
Excreted in breast milk.
Not intended for use in children. Do not administer to adolescents who weigh less than 40 kg (88 lb) because it is a fixed-dose tablet that cannot be adjusted for this population.
Use with caution, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and comorbidity.
Fatal hypersensitivity reactions have been associated with abacavir use and have occurred within hours after reintroduction of abacavir in patients who have no identified history or unrecognized symptoms of hypersensitivity.
Because this is a fixed-dose combination, do not use for patients requiring dose adjustments (eg, CrCl less than 50 mL/min).
Contraindicated in patients with impaired hepatic function because this is a fixed-dose combination that cannot be adjusted for hepatically impaired patients.
Use with caution in patients who have bone marrow compromise evidenced by granulocyte count less than 1,000 cells/mm 3 or Hgb less than 9.5 g/dL.
Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, breast enlargement, and cushingoid appearance have been reported. Mechanism and long-term consequences of these events is unknown.
Contains abacavir, lamivudine, and zidovudine in a fixed-dose tablet. Ensure patient is not receiving abacavir, lamivudine, or zidovudine in any other doseforms. Because the dose cannot be adjusted, do not administer to patients who weigh less than 40 kg or other patients who may require a dose adjustment (eg, dose-related toxicity, hepatic or renal impairment).
Has been reported in patients treated with combination antiretroviral therapy.
Use of abacavir within the 6 months prior to combined antiretroviral therapy may increase the risk of MI.
Myopathy and myositis, with pathological changes similar to that produced by HIV disease, have been associated with prolonged use of zidovudine.
In patients treated with lamivudine for chronic HBV, there is clinical and laboratory evidence of hepatitis exacerbations after discontinuation of lamivudine.
Patients with prolonged prior nucleoside reverse transcriptase inhibitor (NRTI) exposure or who have HIV-1 isolates containing multiple mutations conferring NRTI resistance have limited response to abacavir. Thus, potential cross-resistance between abacavir and other NRTIs should be considered when selecting new regimens for therapy-experienced patients.
Confusion, dizziness, drowsiness, headache, lethargy, nausea, vomiting.
Copyright © 2009 Wolters Kluwer Health.